Eagle Pharmaceuticals Inc Has More Gas To Increase After Today’s Bullish Options Activity

 Eagle Pharmaceuticals Inc Has More Gas To Increase After Today's Bullish Options Activity

In today’s session Eagle Pharmaceuticals Inc (EGRX) registered an unusually high (102) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the December, 2016 call, expecting serious EGRX increase. With 102 contracts traded and 3934 open interest for the Dec, 16 contract, it seems this is a quite bullish bet. The option with symbol: EGRX161216C00085000 closed last at: $1.9 or 81% up. About 18,486 shares traded hands. Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has risen 94.33% since April 22, 2016 and is uptrending. It has outperformed by 88.92% the S&P500.

Analysts await Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to report earnings on February, 23. They expect $2.93 EPS, up 4,085.71% or $2.86 from last year’s $0.07 per share. EGRX’s profit will be $46.61M for 6.70 P/E if the $2.93 EPS becomes a reality. After $0.73 actual EPS reported by Eagle Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 301.37% EPS growth.

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Ratings Coverage

Out of 4 analysts covering Eagle Pharma (NASDAQ:EGRX), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Eagle Pharma has been the topic of 10 analyst reports since July 29, 2015 according to StockzIntelligence Inc. RBC Capital Markets maintained Eagle Pharmaceuticals Inc (NASDAQ:EGRX) rating on Tuesday, May 10. RBC Capital Markets has “Outperform” rating and $78 price target. Piper Jaffray maintained the shares of EGRX in a report on Wednesday, July 29 with “Overweight” rating. The stock has “Outperform” rating given by William Blair on Wednesday, November 2. Mizuho maintained it with “Buy” rating and $62 target price in Wednesday, October 26 report. The stock of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has “Neutral” rating given on Monday, June 20 by Mizuho. RBC Capital Markets maintained the shares of EGRX in a report on Thursday, November 3 with “Outperform” rating. Mizuho initiated the shares of EGRX in a report on Wednesday, December 9 with “Buy” rating. The company was maintained on Friday, February 26 by Mizuho. The rating was upgraded by Mizuho to “Buy” on Thursday, November 3. The stock of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has “Neutral” rating given on Wednesday, November 16 by Mizuho.

According to Zacks Investment Research, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey.”

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company has a market cap of $1.25 billion. The Firm focuses on developing and commercializing injectable products in the critical care and oncology areas. It has a 51.09 P/E ratio. The Company’s product portfolio includes EP-1101 ; Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).

EGRX Company Profile

Eagle Pharmaceuticals, Inc., incorporated on January 2, 2007, is a specialty pharmaceutical company. The Firm focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka). The Firm has over four product candidates in advanced stages of development, and/or under review for approval by the United States Food and Drug Administration (FDA), which include EP-6101 Kangio ready-to-use (RTU) bivalirudin; EP-4104 (dantrolene sodium) (EP-4104) for exertional heat stroke (EHS), and EP-5101 (pemetrexed) (EP-5101). The Company’s near-term product candidate, Kangio is a liquid intravenous form of Angiomax for percutaneous transluminal angioplasty.

More recent Eagle Pharmaceuticals Inc (NASDAQ:EGRX) news were published by: Fool.com which released: “Why Eagle Pharmaceuticals, Inc. Is Soaring 21.6% Today” on November 02, 2016. Also Businesswire.com published the news titled: “Eagle Pharmaceuticals, Inc. Reports Third Quarter 2016 Results” on November 09, 2016. Businesswire.com‘s news article titled: “Eagle Pharmaceuticals to Present at Piper Jaffray 28th Annual Healthcare …” with publication date: November 11, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment